A study supported by the National Institutes of Health (NIH) has found that semaglutide, a key component in drugs like Ozempic and Wegovy, may help extend lifespan and reduce signs of aging in older, healthy mice. The research was led by Danica Chen from the University of California, Berkeley, and compared the effects of semaglutide with calorie restriction, a well-documented method for increasing lifespan in lab animals. The findings suggest that semaglutide not only mimics many of the anti-aging effects of calorie restriction but also offers additional benefits, such as improved exploratory behavior, spatial memory, and better blood-sugar control in the mice. The mice treated with semaglutide also showed enhanced muscle function, improved cognitive abilities, lower levels of inflammation, and faster tissue repair and regeneration. Notably, the median lifespan of the treated mice was nearly 100 days longer than that of the untreated group. This significant increase indicates that semaglutide may affect biological processes related to aging in ways that go beyond the effects of calorie restriction. While these findings are promising, researchers emphasize that more studies are needed to determine whether semaglutide could have similar effects on human aging. The results open the door to exploring GLP-1 drugs as potential tools for addressing aging-related health issues in people, but further clinical trials are essential to confirm these possibilities. The study was funded by several NIH grants, including R01AG063404, R01AG063389, and R01AG082105, highlighting the importance of continued research into aging and potential interventions.